SCHEMBL125177

SCHEMBL125177

CCCC1(O)C=CC(C[C@H](N)C(=O)O)C=C1

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 3/20 0.34
SLC1A2 P43004 3/20 0.34
SLC1A1 P43005 3/20 0.34
GRIK1 P39086 2/20 0.34
GRIK2 Q13002 2/20 0.34
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA3 P42263 1/20 0.33
GRIA4 P48058 1/20 0.33
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13857821 1.00 SLC1A3 (0.34) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL4458615 0.82 IDO1 (0.37) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL7375800 0.80 IDO1 (0.36) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL7200966 0.78 IDO1 (0.36) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL598028 0.77 GRIK1 (0.36) GRIK1GRIK2IDO1TDO2
SCHEMBL15156025 0.77 IDO1 (0.35) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL7241021 0.77 IDO1 (0.35) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL1614569 0.77 IDO1 (0.35) SLC1A3SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL686409 0.76 IDO1 (0.33) SLC1A3SLC1A2SLC1A1IDO1TDO2
SCHEMBL687402 0.76 IDO1 (0.33) SLC1A3SLC1A2SLC1A1IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577575-B2 Methods and compositions for promoting non-natural amino acid-containing protein production AMBRX, INC. (US) 2026-03-17 US claimed
EP-4689127-A1 RF1 KO E. COLI STRAINS Sutro Biopharma, Inc. (US) 2026-02-11 EP claimed
US-12540197-B2 Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates SUTRO BIOPHARMA, INC. (US) 2026-02-03 US claimed
US-20250327074-A1 THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) 2025-10-23 US claimed
US-20250325633-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES Synthorx, Inc. (US) 2025-10-23 US claimed
US-20250325632-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES Synthorx, Inc. (US) 2025-10-23 US claimed
US-20250304723-A1 MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE SUTRO BIOPHARMA, INC. 2025-10-02 US claimed
US-12427201-B2 Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates SUTRO BIOPHARMA, INC. (US) 2025-09-30 US claimed
US-12404512-B2 Method for optimizing antibody expression AMBRX, INC. (US) 2025-09-02 US claimed
EP-3788149-B1 A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION AMBRX INC (US) 2025-08-27 EP claimed
US-20050208536-A1 Comprises ribonuclease barnase marker gene; libraries; drug resistance THE SCRIPPS RESEARCH INSTITUTE (US) 2005-09-22 US claimed
EP-1456360-A4 METHODS AND COMPOSITION FOR THE PRODUCTION OF ORTHOGANAL TRNA-AMINOACYLTRNA SYNTHETASE PAIRS SCRIPPS RESEARCH INST (US) 2005-05-25 EP claimed
US-20050009049-A1 Expanding the eukaryotic genetic code THE SCRIPPS RESEARCH INSTITUTE (US) 2005-01-13 US claimed
EP-1490483-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS The Scripps Research Institute (US) 2004-12-29 EP claimed
WO-2004094593-A2 EXPANDING THE EUKARYOTIC GENETIC CODE THE SCRIPPS RESEARCH INSTITUTE (US) 2004-11-04 WO claimed
EP-1456360-A2 METHODS AND COMPOSITION FOR THE PRODUCTION OF ORTHOGANAL TRNA-AMINOACYLTRNA SYNTHETASE PAIRS The Scripps Research Institute (US) 2004-09-15 EP claimed
US-20030108885-A1 Comprises ribonuclease barnase marker gene; recombination/genetic engineering; libraries; drug resistance THE SCRIPPS RESEARCH INSTITUTE (US) 2003-06-12 US claimed
US-20030082575-A1 Translation system for use in the generation of protein containing adjusted amino acid sequences THE SCRIPPS RESEARCH INSTITUTE (US) 2003-05-01 US claimed
WO-2002086075-A2 METHODS AND COMPOSITION FOR THE PRODUCTION OF ORTHOGANAL TRNA-AMINOACYLTRNA SYNTHETASE PAIRS THE SCRIPPS RESEARCH INSTITUTE (US) 2002-10-31 WO claimed
WO-2002085923-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS THE SCRIPPS RESEARCH INSTITUTE (US) 2002-10-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325633-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES IL2, IL2RA, IL15 SLC1A3 3456/4885SLC1A2 2531/4885SLC1A1 3400/4885
US-12427201-B2 Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates FOLR1, FOLR2, DHFR SLC1A3 632/4885SLC1A2 792/4885SLC1A1 473/4885
US-20250304723-A1 MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE FCGR2A, FCGR3B, FCGR1A SLC1A3 457/4885SLC1A2 1057/4885SLC1A1 643/4885
US-20050009049-A1 Expanding the eukaryotic genetic code NSUN3, AARS1, TRMT1 SLC1A3 684/4885SLC1A2 634/4885SLC1A1 468/4885
US-12577575-B2 Methods and compositions for promoting non-natural amino acid-containing protein production AARS1, NSUN3, UPF1 SLC1A3 873/4885SLC1A2 999/4885SLC1A1 823/4885
US-20050208536-A1 Comprises ribonuclease barnase marker gene; libraries; drug resistance RNASEL, RNASEH1, RNASE1 SLC1A3 1650/4885SLC1A2 1543/4885SLC1A1 1159/4885
US-20250325632-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES IL2, IL2RA, IL36G SLC1A3 4236/4885SLC1A2 3478/4885SLC1A1 3969/4885
US-12540197-B2 Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates VSIG8, F13B, HNRNPH3 SLC1A3 1845/4885SLC1A2 2006/4885SLC1A1 1629/4885
US-20030108885-A1 Comprises ribonuclease barnase marker gene; recombination/genetic engineering; libraries; drug resistance RNASEL, RNASEH1, RNASE1 SLC1A3 2115/4885SLC1A2 1964/4885SLC1A1 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.